10x Genomics holder plans sale of 2,207 shares

10x Genomics, Inc. (TXG) is the issuer for a proposed sale of its Class A common stock under Rule 144 by stockholder Shehnaaz Suliman, with J.P.

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) is the issuer for a proposed sale of its Class A common stock under Rule 144 by stockholder Shehnaaz Suliman, with J.P. Morgan Securities LLC acting as agent and attorney-in-fact. The notice covers a planned sale of 2,207 Class A common shares, associated with RSU vesting, to be sold through J.P. Morgan Securities LLC. The filing states an aggregate market value for these securities of $143,719.84 and lists 120,212,296 shares of Class A common stock outstanding. It also notes that, in the past three months, Suliman sold 5,723 shares of Class A common stock for $186,756.21.

Key Figures

Shares proposed to be sold: 2,207 shares of Class A Common Aggregate market value of proposed sale: $143,719.84 Shares outstanding: 120,212,296 shares +4 more

7 metrics

Shares proposed to be sold 2,207 shares of Class A Common Planned Rule 144 sale by Shehnaaz Suliman

Aggregate market value of proposed sale $143,719.84 Value for 2,207 shares covered by the notice

Shares outstanding 120,212,296 shares Class A common stock outstanding for 10x Genomics, Inc.

Shares sold in past 3 months 5,723 shares Sale on 06/16/2026 by Shehnaaz Suliman

Aggregate amount from past sale $186,756.21 For 5,723 shares sold on 06/16/2026

Acquisition date of RSU shares 08/21/2021 Compensation-related RSU acquisition for shares to be sold

Planned RSU vesting sale date 08/21/2026 Date tied to RSU vesting for proposed sale

Key Terms

Rule 144, RSU Vesting, attorney-in-fact, aggregate market value

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU Vesting financial

"Class A Common | 08/21/2026 | RSU Vesting | Issuer"

RSU vesting is the process by which restricted stock units — a promise by a company to give shares to an employee — become actual, owned shares over time or when certain goals are met. Investors care because vested shares can dilute existing ownership when issued, and the timing of vesting affects when employees can sell shares, which can influence share supply, insider selling patterns, and company incentives.

attorney-in-fact regulatory

"as agent and attorney-in-fact for Shehnaaz Suliman"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

aggregate market value financial

"2207 | 143719.84 | 120212296 | 08/24/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for TXG by Shehnaaz Suliman disclose?

It discloses a proposed sale under Rule 144 of 2,207 shares of 10x Genomics Class A common stock, related to RSU vesting, to be sold through J.P. Morgan Securities LLC, along with details of prior sales in the last three months.

How many TXG shares are planned to be sold under this Rule 144 notice?

The notice covers a proposed sale of 2,207 shares of 10x Genomics Class A common stock, associated with RSU vesting and to be sold through J.P. Morgan Securities LLC.

What is the stated market value of the TXG shares in this Form 144?

The filing states an aggregate market value of $143,719.84 for the 2,207 shares of 10x Genomics Class A common stock covered by this Rule 144 notice.

How many 10x Genomics (TXG) shares are outstanding according to this filing?

The filing lists 120,212,296 shares of 10x Genomics Class A common stock outstanding, providing context for the size of the proposed Rule 144 sale.

What TXG stock sales has Shehnaaz Suliman made in the past three months?

Over the past three months, Shehnaaz Suliman sold 5,723 shares of 10x Genomics Class A common stock on 06/16/2026 for an aggregate amount of $186,756.21.

What is the origin of the TXG shares to be sold under this Form 144?

The 2,207 shares to be sold are tied to RSU vesting, acquired from the issuer as compensation with an acquisition date of 08/21/2021.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 05:28 PM EDT Accepted by SEC EDGAR 08/24/2026 - 05:27 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001713070
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	10X Genomics, Inc.
SEC File Number	001-39035
Address of Issuer	6230 Stoneridge Mall Road Pleasanton CALIFORNIA 94588
Phone	925-401-7300
Name of Person for Whose Account the Securities are To Be Sold	Shehnaaz Suliman
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common	JP Morgan Securities LLC 270 Park Avenue, 10th Floor New York NY 10017	2207	143719.84	120212296	08/24/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common	08/21/2026	RSU Vesting	Issuer			2207	08/21/2021	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Shehnaaz Suliman Care of TXG Genomics Inc 6230 Stoneridge Mall Road Pleasanton CA 94588	Class A Common	06/16/2026	5723	186756.21

144: Remarks and Signature

Remarks
Date of Notice	08/24/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Shehnaaz Suliman
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)